SYMPOSIUM |
|
Year : 2007 | Volume
: 55
| Issue : 6 | Page : 427-430 |
|
Pegaptanib sodium for ocular vascular disease
Dhananjay Shukla1, Perumalsamy Namperumalsamy2, Mauro Goldbaum3, Emmett T Cunningham Jr4
1 Retina-Vitreous Service, Aravind Eye Hospital and Postgraduate Institute, Anna Nagar, Madurai, India 2 Chairman, Aravind Eye Care System, Anna Nagar, Madurai, India 3 OSI Eyetech, Inc., New York, USA 4 Director, The Uveitis Service, California Pacific Medical Center, San Francisco, California and Adjunct Clinical Professor, Department of Ophthalmology, Stanford University School of Medicine, Stanford, California, USA
Correspondence Address:
Emmett T Cunningham Jr 801 Gateway Boulevard, Suite 410, South San Francisco, California 94080 USA
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/0301-4738.36476
|
|
Pegaptanib sodium (Macugen™) is a selective RNA aptamer that inhibits vascular endothelial growth factor (VEGF) 165 , the VEGF isoform primarily responsible for pathologic ocular neovascularization and vascular permeability, while sparing the physiological isoform VEGF 121 . After more than 10 years in development and preclinical study, pegaptanib was shown in clinical trials to be effective in treating choroidal neovascularization associated with age-related macular degeneration. Its excellent ocular and systemic safety profile has also been confirmed in patients receiving up to three years of therapy. Early, well-controlled studies further suggest that pegaptanib may provide therapeutic benefit for patients with diabetic macular edema, proliferative diabetic retinopathy and retinal vein occlusion. Notably, pegaptanib was the first available aptamer approved for therapeutic use in humans and the first VEGF inhibitor available for the treatment of ocular vascular diseases. |
|
|
|
[FULL TEXT] [PDF]* |
|
|
|